Why Buy stock in ADMA Biologics Inc. (ADMA)? – Marketing Sentinel

Why Buy stock in ADMA Biologics Inc. (ADMA)?

ADMA Biologics Inc. (NASDAQ:ADMA) has a beta value of 1.35 and has seen 5,318,886 shares traded in the last trading session. The company, currently valued at $241.17 Million, closed the last trade at $1.96 per share which meant it lost -$0.09 on the day or -4.39% during that session. The ADMA stock price is -114.29% off its 52-week high price of $4.2 and 19.9% above the 52-week low of $1.57. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.31 Million shares traded. The 3-month trading volume is 3.79 Million shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

The consensus among analysts is that ADMA Biologics Inc. (ADMA) is a Buy stock at the moment, with a recommendation rating of 1.8. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. None out of 5 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.17.

ADMA Biologics Inc. (NASDAQ:ADMA) trade information

Despite being -4.39% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Apr 28 when the ADMA stock price touched $2.63 or saw a rise of 25.48%. Year-to-date, ADMA Biologics Inc. shares have moved 0.51%, while the 5-day performance has seen it change 3.16%. Over the past 30 days, the shares of ADMA Biologics Inc. (NASDAQ:ADMA) have changed 14.62%. Short interest in the company has seen 10.33 Million shares shorted with days to cover at 2.73.

Wall Street analysts have a consensus price target for the stock at $8.2, which means that the shares’ value could jump 318.37% from current levels. The projected low price target is $6 while the price target rests at a high of $11. In that case, then, we find that the current price level is +461.22% off the targeted high while a plunge would see the stock lose 206.12% from current levels.

ADMA Biologics Inc. (ADMA) estimates and forecasts

Figures show that ADMA Biologics Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -4.85% over the past 6 months, with this year growth rate of 31.82%, compared to 8.1% for the industry. Other than that, the company has, however Increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 34.6% and 30.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be +66.9%.

4 analysts offering their estimates for the company have set an average revenue estimate of $14.55 Million for the current quarter. 4 have an estimated revenue figure of $15.68 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $10.2 Million and $7.79 Million respectively for this quarter and the next, and analysts expect sales will grow by 42.6% for the current quarter and 101.3% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +12.6% over the past 5 years. Earnings growth for 2021 is a modest +1%.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


ADMA Biologics Inc. (NASDAQ:ADMA)’s Major holders

Insiders own 1.92% of the company shares, while shares held by institutions stand at 42.8% with a share float percentage of 43.63%. Investors are also buoyed by the number of investors in a company, with ADMA Biologics Inc. having a total of 129 institutions that hold shares in the company. The top two institutional holders are Perceptive Advisors Llc with over 16.58 Million shares worth more than $32.34 Million. As of December 30, 2020, Perceptive Advisors Llc held 13.48% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 5.42 Million shares as of December 30, 2020. The firm’s total holdings are worth over $10.58 Million and represent 4.41% of shares outstanding.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of December 30, 2020, the former fund manager holds about 1.92% shares in the company for having 2363570 shares of worth $4.61 Million while later fund manager owns 1.54 Million shares of worth $2.71 Million as of March 30, 2021, which makes it owner of about 1.25% of company’s outstanding stock.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.